aavantgarde_logo.jpg
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting
23 avr. 2024 02h00 HE | AAVantgarde Bio
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at ASGCT 2024
logo_ProQR-150x150.png
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
22 avr. 2024 16h31 HE | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
SANIA LOGO.png
Sania Therapeutics to Present at the American Society of Gene & Cell Therapy Annual Meeting
11 avr. 2024 07h00 HE | Sania Therapeutics
Sania Therapeutics to Present at the American Society of Gene & Cell Therapy Annual Meeting LONDON, UK & NEW YORK, USA – 11 April 2024, Sania Therapeutics (the “Company”), focused on...
EpicBioCMYK300dpi.png
Epic Bio Announces Robust Slate of Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
09 avr. 2024 09h00 HE | Epic Bio
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced the...
Coave Logo.png
Coave Therapeutics to Present at Upcoming Conferences
27 mars 2024 07h00 HE | Coave Therapeutics
Paris, France, March 27, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following...
outpace logo.png
Outpace Bio to Present New Data on OutSmart™ IL-2/15, a CAR T Cell-Produced Designed Cytokine with Tumor-Localized Immune Cell Activity, at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
18 mai 2023 08h00 HE | Outpace Bio
Seattle, WA, May 18, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, today announced it will...
locanabio-logo-rgb.jpg
Locanabio Presents Preclinical Data from its Vectorized snRNA Exon Skipping Program for DMD and Cas13d Multi-targeting Program for C9orf72 ALS at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
16 mai 2023 06h00 HE | Locanabio, Inc.
LBIO-115 demonstrates robust exon 51 skipping resulting in high levels of dystrophin restoration in patient-derived muscle cells and an in vivo DMD disease model Cas13d Multi-targeting efficiently...
Outpace Bio, a Leader in Protein Design for Cell Therapy, Announces Presentation at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
09 mai 2023 09h00 HE | Outpace Bio
Seattle, WA, May 09, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, today announced that an...
NKGen Biotech RGB small.jpg
NKGen Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
02 mai 2023 16h35 HE | NKGen Biotech
SANTA ANA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous,...
3787276_Codiak_Logo_White_CMYK.jpg
Codiak Presents New Preclinical Data at ASGCT 2022 on Exosome-Based Strategy to Enhance AAV Gene Therapy
17 mai 2022 07h00 HE | Codiak BioSciences, Inc.
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a...